Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01569815 | Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function | completed | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 3 | Oct 19, 2015 | clinicaltrials |
| NCT00375505 | The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss | completed | Phase 3 | 70 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 7, 2015 | clinicaltrials |
| NCT00510068 | Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors(RADIANT-3) | completed | Phase 3 | 410 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 1, 2015 | clinicaltrials |
| NCT01249456 | Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients | completed | — | 392 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 25, 2015 | clinicaltrials |
| NCT01379534 | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | completed | Phase 2 | 53 | Novartis PharmaceuticalsINDUSTRY | 7 | May 20, 2015 | clinicaltrials |
| NCT01220648 | Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)(NICOLI) | completed | Phase 1 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | May 5, 2015 | clinicaltrials |
| NCT00172042 | A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 437 | Novartis PharmaceuticalsINDUSTRY | 15 | May 4, 2015 | clinicaltrials |
| NCT00582426 | Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea(LARCID) | completed | Phase 3 | 139 | Novartis PharmaceuticalsINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT01613053 | Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination(MACS2226) | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 24, 2015 | clinicaltrials |
| NCT01217177 | A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer(PHOENIX I) | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 3, 2015 | clinicaltrials |
| NCT00584740 | Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease | terminated | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2015 | clinicaltrials |
| NCT01324492 | Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor(\MACS1304) | completed | Phase 1 | 16 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00333229 | A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss | terminated | Phase 4 | 11 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 25, 2014 | clinicaltrials |
| NCT00412061 | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor(RADIANT-2) | completed | Phase 3 | 429 | Novartis PharmaceuticalsINDUSTRY | 15 | Nov 21, 2014 | clinicaltrials |
| NCT01610050 | A Phase I Study of LFA102 in Japanese Patients | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 11, 2014 | clinicaltrials |
| NCT00320710 | Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer | completed | Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 22, 2014 | clinicaltrials |
| NCT00237185 | A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene | completed | Phase 2 | 148 | Novartis PharmaceuticalsINDUSTRY | 3 | Aug 19, 2014 | clinicaltrials |
| NCT01129336 | Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients(MACS1295) | completed | Phase 4 | 44 | Novartis PharmaceuticalsINDUSTRY | 1 | May 20, 2014 | clinicaltrials |
| NCT00242567 | Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer | completed | Phase 3 | 522 | Novartis PharmaceuticalsINDUSTRY | 10 | May 7, 2014 | clinicaltrials |
| NCT00751036 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg(MACS0375) | terminated | Phase 3 | 94 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 26, 2014 | clinicaltrials |
| NCT00171834 | Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT00035087 | EPO906 Therapy in Patients With Advanced Colorectal Cancer | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00333840 | Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | completed | Phase 3 | 1,106 | Novartis PharmaceuticalsINDUSTRY | 16 | Oct 14, 2013 | clinicaltrials |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00690430 | Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | completed | Phase 3 | 186 | Novartis PharmaceuticalsINDUSTRY | 16 | Jul 30, 2013 | clinicaltrials |
| NCT00107237 | AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 16 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 12, 2013 | clinicaltrials |
| NCT00441155 | Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 3 | May 13, 2013 | clinicaltrials |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | completed | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 11 | May 10, 2013 | clinicaltrials |
| NCT00005073 | Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms | terminated | Phase 3 | 544 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00006368 | Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00006370 | Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer | completed | Phase 2 | 275 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00093639 | Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate | completed | Phase 1 / Phase 2 | — | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00420485 | Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 7 | Apr 19, 2013 | clinicaltrials |
| NCT00828594 | Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 130 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 11, 2013 | clinicaltrials |
| NCT00411580 | Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD) | completed | Phase 1 | 58 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 29, 2013 | clinicaltrials |
| NCT00107016 | Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women | completed | Phase 2 | 267 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 4, 2013 | clinicaltrials |
| NCT00741377 | A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients | completed | Phase 1 | 28 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 18, 2013 | clinicaltrials |
| NCT00457119 | Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients | completed | Phase 1 | 69 | Novartis PharmaceuticalsINDUSTRY | 3 | Feb 12, 2013 | clinicaltrials |
| NCT00410124 | RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib(RECORD-1) | completed | Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 10 | Jan 15, 2013 | clinicaltrials |
| NCT00699296 | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 27, 2012 | clinicaltrials |
| NCT00478634 | A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 19 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 2, 2012 | clinicaltrials |
| NCT00108108 | Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy | terminated | Phase 1 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 1, 2012 | clinicaltrials |
| NCT00171977 | Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) | completed | Phase 4 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00427583 | Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | terminated | Phase 2 / Phase 3 | 11 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01098838 | Safety and Efficacy of LCL161 in Patients With Solid Tumors | completed | Phase 1 | 71 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 3, 2012 | clinicaltrials |
| NCT00905593 | Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | approved for marketing | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
| NCT01290406 | BEZ235 Trial in Patients With Advanced Endometrial Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 21, 2012 | clinicaltrials |
| NCT00471328 | Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib(ENEST) | completed | Phase 3 | 248 | Novartis PharmaceuticalsINDUSTRY | 13 | Jun 12, 2012 | clinicaltrials |
| NCT01288092 | BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 7, 2012 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials